Debolina Ganguly
banner
debolina-ganguly.bsky.social
Debolina Ganguly
@debolina-ganguly.bsky.social
Parker Scholar | Post doc in Cancer Immunology at DFCI/HMS in Agudolab| PhD in Cancer biology from Brekkenlab at UTSW | 🇮🇳🇺🇸| she/her/hers
Reposted by Debolina Ganguly
Our paper online now, CAF molecular phenotypes are more conserved than we thought across organs. Plus we now know more details about apCAFs. Please check it out 👉 Cancer Cell www.cell.com/cancer-cell/...
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches
Chen et al. identify two distinct antigen-presenting cancer-associated fibroblast (apCAF) populations across multiple cancer types. Mesothelial-related apCAFs locate near cancer cells while fibrocyte-...
www.cell.com
September 25, 2025 at 4:07 PM
Reposted by Debolina Ganguly
www.sciencedirect.com/science/arti...

Stellar postdoc @debolina-ganguly.bsky.social and I wrote this spotlight for a super cool paper on the systemic effects of metatasis. The organ of metastatic diseases makes A BIG difference! Highly recommended paper in @cp-cancercell.bsky.social
Bone appetite: bone-derived factors feed distant immune suppression
The site of metastatic disease influences treatment response. A recent study in Cancer Cell by Cheng et al. revealed that bone metastases systemically…
www.sciencedirect.com
July 18, 2025 at 1:44 PM
Reposted by Debolina Ganguly
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad.bsky.social lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13)
www.nature.com/articles/s41...
Neutrophils drive vascular occlusion, tumour necrosis and metastasis - Nature
Neutrophils actively induce tumour necrosis, driving vascular occlusion, pleomorphic necrosis and metastasis.
www.nature.com
July 17, 2025 at 11:28 AM
Reposted by Debolina Ganguly
🎉🎉🥳 couldn’t be more proud of my PI!!! 🤩
June 13, 2025 at 4:59 PM
Reposted by Debolina Ganguly
Harvard president receives standing ovation during commencement.
May 29, 2025 at 11:40 PM
Reposted by Debolina Ganguly
👍Yeah: Just out in @naturecancer.bsky.social from my lab @cniostopcancer.bsky.social
Here, a video highlighting mechanisms of immune suppression in melanoma (hope you like the hot-to-cold shift via DCs)
Implications for immune resistance in different tumor types below
www.nature.com/articles/s43...
March 29, 2025 at 7:20 PM
Reposted by Debolina Ganguly
Why do brain metastases resist #immunotherapy — even when the same cancer responds outside the #brain? 🧠🧪💥

We just published a study diving into this question ⏬

Led by an amazing (former) PhD student in my lab —Vladimir Wischnewski 🎉

🧵 1/

@cp-cellreports.bsky.social

www.cell.com/cell-reports...
March 31, 2025 at 12:20 PM
Reposted by Debolina Ganguly
1/2024 was a big year for metastasis research! Check out our top articles on metastasis research from the year. The field is driving progress and promise for patients with metastatic cancer.

Join MRS for monthly updates on all things metastasis:
metastasis-research.org/for-research...
Membership | Metastasis Research
metastasis-research.org
December 23, 2024 at 3:55 PM
Reposted by Debolina Ganguly
So excited to share our new paper working w/ David Lyden, Han Kim & Jackie Bromberg (WCM), led by the amazing Inbal Wortzel & Ifé Akano where we revealed a new & unexpected function for chromatin on the surface of exosomes in #cancer #metastasis @ Nature Cancer!

www.nature.com/articles/s43...
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression - Nature Cancer
Lyden and colleagues find that immune developmental genes, such as apoptotic peptidase activating factor 1 (APAF1), support DNA packaging on the surface of tumor-derived extracellular vesicles that ar...
www.nature.com
December 4, 2024 at 2:09 AM
Reposted by Debolina Ganguly
Hi #immunosky @rafrancescone.bsky.social and I are looking for a postdoc candidate interested in immunology, with experience in flow cytometry, to run projects exploring mechanisms of immunosuppression in pancreatic cancer. Come to beautiful Michigan! Official announcement soon. DM us
November 30, 2024 at 3:56 PM
Reposted by Debolina Ganguly
1/23 Big news for the #ObenaufLab! So excited to finally share our new study providing another puzzle piece, why immunotherapy fails in many tumors, now out in @Nature 🧵👇 www.nature.com/articles/s41...
November 27, 2024 at 5:58 PM
Reposted by Debolina Ganguly
Comprehensive single-cell aging atlas of healthy mammary tissues reveals shared epigenomic and transcriptomic signatures of aging and Cancer. #NatureAging #Aging #scisky #Medsky #News #Cancer

Open Access
www.nature.com/articles/s43...
November 26, 2024 at 7:48 AM
Reposted by Debolina Ganguly
There are ~40k postdocs in the US, according to the NIH. While PhD students generally have good support (their committees, external advisors, and classmates), the postdocs do not. To help with this, we're starting the 'Postdoc Night Science' club in Boston this Thursday! (1/3)
November 19, 2024 at 5:00 AM
It’s great to see this pre-print from the @huoconghuang.bsky.social! Must read for people interested in apCafs!
November 18, 2024 at 4:57 PM
Reposted by Debolina Ganguly
My first Bluesky meeting post: @megeblad.bsky.social kicking off the AACR tumor-body interactions meeting.
November 17, 2024 at 11:04 PM
Reposted by Debolina Ganguly
🐦➡️🦋 Looking to rebuild your network on Bluesky by reconnecting with your existing X/Twitter contacts? The Skylink browser extension makes it easy!
chromewebstore.google.com/detail/sky-f...

Thanks @jmschreiber91.bsky.social!
#scicomm #cancer #tumorimmunology
Sky Follower Bridge - Chrome Web Store
Instantly find and follow the same users from your Twitter follows on Bluesky.
chromewebstore.google.com
November 17, 2024 at 10:56 AM